ATLASATLAS fair value
DKK 3,293
Below fair value · 9% discount
Range: DKK 2,334–DKK 4,917Fair valuePrice
Genmab (GMAB.CO)
Genmab stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · Nasdaq Copenhagen · Denmark
DKK 2,997▲ +1.11%
Prices as of Oct 27, 2026 · DKK
Chance of rising in 1 month
50%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Genmab in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Genmab
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS estimates Genmab's fair value at about DKK 3,293 per share (reasonable range: DKK 2,334 to DKK 4,917). At DKK 2,997, the stock trades 9% below it.
It is calculated with a discounted cash-flow model. Confidence in the estimate is medium. It is an estimate, not a promise: if the company's results change, so does its fair value.
ATLAS's model gives Genmab a 50% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between DKK 2,814 and DKK 3,193; in 9 out of 10, between DKK 2,515 and DKK 3,573. Estimated annual volatility is 38%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- DKK 154B
- Market cap (USD)
- $22.9B
- P/E ratio
- 32.1
- 52-week high
- DKK 3,060
- 52-week low
- DKK 1,512
- Revenue (12 months)
- $4.1B
- Gross margin
- 93.0%
- Operating margin
- 35.2%
- Net margin
- 19.1%
- Beta
- 0.65
What this means
These are two different questions: fair value looks at the business (what it is worth given what it earns) and the odds look at the price over the next month. Genmab sits below fair value and its odds of rising over a month are close to a coin flip. An expensive stock can keep climbing and a cheap one can keep falling, which is why ATLAS shows the two readings separately.
Over the last 52 weeks GMAB.CO has traded between DKK 1,512 and DKK 3,060. Today it is 2.1% below that high and 98% above its low.
On the business: net margin is 19.1%; it trades at 32.1 times earnings.
Its beta is 0.65: it tends to move less than the market.
About the company
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark.
Want to see everything about Genmab?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What is Genmab (GMAB.CO) fair value?
About DKK 3,293 per share according to ATLAS (reasonable range: DKK 2,334 to DKK 4,917). With the stock at DKK 2,997, it is 9% below it.
What is the chance GMAB.CO goes up next month?
50%: close to a coin flip. In half of the simulated outcomes, GMAB.CO ends the month between DKK 2,814 and DKK 3,193.
How big is Genmab and what is its P/E ratio?
Genmab's market capitalization is DKK 154B. Its price-to-earnings (P/E) ratio is 32.1: you pay DKK 32.1 for each DKK 1.00 of yearly earnings.
How volatile is GMAB.CO?
ATLAS estimates annual volatility at 38%. In a typical month, half of the outcomes end between DKK 2,814 and DKK 3,193.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer